Sharechat Logo

BNZ 1Q profit sinks 56 percent on impairments, fair-value movements; interest margins fatten

Monday 18th February 2013

Text too small?

Bank of New Zealand first-quarter profit sank 56 percent after the local unit of National Australia Bank took bigger impairment charges on its loan book and wrote down the value of financial instruments, even as it squeezed more from its interest rate margins.

Net profit fell to $126 million in the three months ended Dec. 31 from $289 million a year earlier, according to the lender's general disclosure statement. Net interest income rose 7.8 percent to $388 million, with the lender increasing net margins to 40.5 percent from 38.5 percent a year earlier.

The bottom line was hit by a $74 million loss on the fair value of its financial instruments, compared to a $139 million gain a year earlier, and a $36 million impairment charge on its credit exposures, up from a $3 million charge in 2011.

Earlier this month, NAB said the New Zealand banking unit's cash earnings were up on volume growth and higher fee income.

BNZ lifted its home loans to $28.49 billion as at Dec. 31 from $28.13 billion three months earlier, and net loans grew to $59.78 billion from $58.92 billion. The lender's term deposit slipped to $22.13 billion as at Dec. 31 from $22.36 billion at the end of September.

 

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors